Rare, chronic, medically complex.
21 conditions across eight clusters where the published literature is rich, the specialist landscape is uneven, and integrated synthesis is the work nobody else is doing. We take on cases beyond this list — apply anyway if your situation doesn't fit cleanly.
5 conditions.
A heritable connective tissue disorder affecting roughly 1 in 800 people. Causes joint hypermobility, chronic pain, and multi-system involvement spanning rheumatology, cardiology, GI, and autonomic dysfunction.
An immunologic condition in which mast cells inappropriately release inflammatory mediators, producing multi-system symptoms across skin, GI, cardiovascular, and neurologic domains. Frequently overlaps with hEDS and POTS.
A form of dysautonomia affecting approximately 1% of developed-country populations. Patients average six years and seven providers before diagnosis, with 83% initially misdiagnosed as a psychological condition.
A peripheral neuropathy affecting unmyelinated nerve fibers, causing burning pain, autonomic dysfunction, and sensory disturbance. Frequently underlies or coexists with POTS, fibromyalgia, hEDS, and Long COVID.
A leak of cerebrospinal fluid from the spinal dura — producing positional headaches, cognitive symptoms, and a diagnostic odyssey that routinely lasts years before reaching one of the handful of centers that can find and treat it.
4 conditions.
A rare adipose disorder characterized by painful subcutaneous lipomas, chronic fatigue, and cognitive symptoms. Severely under-recognized; clusters with lipedema and Madelung's disease.
An inherited adipose disorder producing multiple, well-circumscribed lipomas across the trunk and extremities. Often presents alongside other adipose tissue disorders.
A chronic, progressive adipose tissue disorder affecting an estimated 10% of women worldwide. Characterized by symmetric, painful fat deposition in the lower body, often misdiagnosed as obesity or lymphedema.
A rare adipose tissue disorder characterized by symmetric, non-encapsulated lipoma growth, most often in the neck, shoulders, and upper trunk. Frequently associated with metabolic and neurologic comorbidities.
3 conditions.
A chronic central sensitization syndrome affecting 1-3% of the global population. Frequently overlaps with ME/CFS, small fiber neuropathy, and sleep architecture disorders.
Persistent post-acute sequelae of SARS-CoV-2 infection affecting 20-40% of infected individuals. Heavily overlapping with ME/CFS, POTS, and MCAS — demanding integrated multi-system evaluation.
A complex multi-system illness affecting an estimated 17-24 million people worldwide, with over 60% undiagnosed. Defined by post-exertional malaise, cognitive dysfunction, and orthostatic intolerance.
3 conditions.
A chronic inflammatory condition affecting roughly 190 million women worldwide, with average diagnostic delays of 7-10 years. Frequently coexists with adenomyosis, interstitial cystitis, MCAS, and hEDS.
Delayed gastric emptying without mechanical obstruction, producing chronic nausea, early satiety, and weight loss. Strongly associated with POTS, hEDS, diabetes, and post-viral syndromes.
A chronic bladder pain condition with strong comorbidity with endometriosis, MCAS, and hEDS. Often misdiagnosed as recurrent UTI; requires multi-system pelvic and immunologic workup.
2 conditions.
An emerging tick-borne allergy to mammalian meat and byproducts. Only 5% of healthcare providers feel confident diagnosing it; presentations range from delayed GI symptoms to anaphylaxis.
A genetic trait producing elevated baseline tryptase and a constellation of mast cell, connective tissue, and autonomic symptoms. Increasingly recognized as a modifier of MCAS and hEDS severity.
2 conditions.
A multi-system granulomatous disease with an estimated 1.2 million cases worldwide. Most commonly affects the lungs but can involve the heart, nervous system, eyes, skin, and other organs.
A rare autoimmune connective tissue disease affecting approximately 1.5 million people globally. Causes progressive fibrosis of skin and internal organs, demanding coordinated management across pulmonary, GI, renal, and vascular domains.
1 condition.
1 condition.
Don’t see your condition?
The list above is what we’ve studied most deeply. Our service extends well beyond it — rare diseases, unresolved symptom clusters, post-diagnosis optimization. Tell us your situation and we’ll be honest about whether we can advance your case.